Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neuroptix names new COO
Most recently, Dr Cagle has served as senior vice president of R&D and chief scientific officer of Alcon Laboratories, a subsidiary of Alcon, Inc, an eye care company.
Most recently, Dr Cagle has served as senior vice president of R&D and chief scientific officer of Alcon Laboratories, a subsidiary of Alcon, Inc, an eye care company.
Schering-Plough has selected Huya to identify and present to Schering-Plough on an exclusive basis proprietary lead, preclinical and clinical drug candidates in specific therapeutic areas that originate in
Under the new agreement, Fenwal will supply Cerus with finished disposable kits for the Intercept platelet and plasma systems through the end of 2013. Claes Glassell, president and
Mr Shanahan is the former president of Colgate-Palmolive Company and currently serves on the board of directors of Visa, Diageo and MSD Ignition, a privately held company. Mr
With the completion of this pivotal phase, Musculoskeletal Transplant Foundation (MTF) has successfully delivered to Orthofix a conclusive data package meeting the specifications provided by Orthofix under the
According to the company, the ViaDerm system provides a self-administered solution that enables the safe, reproducible and accurate delivery of a broad range of product candidates, including hydrophilic
Under the terms of the agreement, Teva will finance Jexys’s R&D program for the development of a high throughput drug discovery platform and in return will receive a
The products include Proteoderm’s special high end formulation and an over-the-counter formulation, currently under development. Proteoderm intends to sell to Sinoquest the pre-mixed material in bulk and a
Ortho-McNeil’s Phase I program will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of APD597 in single and multiple ascending dose studies in healthy volunteers. Ortho-McNeil’s planned clinical studies
The study is an open-label, dose-escalation trial expected to enroll up to 18 patients and to test three dose levels of FG-3019 administered via infusion every two weeks.